变态反应肿瘤学(AllergoOncology)是由变态反应学与肿瘤学合成的名词。 变态反应与肿瘤的关系早在数十年前就 被关注和研究。 1960 年代首次发现了变态反应与肿瘤发病间存在负相关关系。 此后,该领域中有关基础、转化和临床的相关 研究层出不穷。 2014 年由 Erika Jensen-Jarolim 教授牵头在欧洲变态反应与临床免疫学会(EAACI)成立了跨学科、跨领域的 变态反应肿瘤学工作组,旨在建立常态化的变态反应肿瘤学成果交流平台,促进该学科深入持续发展。 工作组关注变态反应 和肿瘤学的交叉点,致力于免疫监视、免疫调节和 IgE 介导的肿瘤免疫治疗等研究,发布了 5 个变态反应肿瘤学的立场文 件,促进了变态反应的核心理论向抗肿瘤临床实用技术转化,希望进一步提高肿瘤临床疗效。 本文结合变态反应与肿瘤学 领域相关文献,从变态反应与肿瘤间的负相关性、变态反应重要分子 IgE 的抗肿瘤效应、免疫细胞和分子以及微生物群分 别在变态反应和肿瘤中的作用和变态反应肿瘤学的转化应用等方面,对变态反应肿瘤学立场文件进行归纳、比较、总结及 要点解读。

AllergoOncology is a combination of allergy and oncology. The relationship between allergy and tumor has been discussed and studied decades ago. In the 1960s a negative correlation between allergy and tumor morbidity was first discovered. Since then there has been an endless stream of related researches on basic translational and clinical medicine in this field. In 2014 a Task Force on AllergoOncology was established at the European Association of Allergy and Clinical Immunology EAACI led by Professor Erika Jensen-Jarolim aiming to establish a routine platform for allergy oncology achievements. Focusing on the intersection of allergy and oncology the working group is dedicated to research on immune surveillance immune regulation and IgE-mediated tumor immune responses and has issued 5 position papers on AllergoOncology. It has promoted the transformation of the core theory of allergy into clinical practical cancer treatment and is expected to further improve the therapeutic efficacy efficacy of tumors. This article interprets the position papers of AllergoOncology from the negative correlation between allergy and tumor effectors cells and molecules and microbiota in allergy and cancer and translational strategies in AllergoOncology based on novel insights into the field of AllergoOncology.